Skip to content
Screener

Bio-Rad Laboratories BIO Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Abbott logo
AbbottABT
$3M-91.4%
MaxCyte logo
MaxCyteMXCT
$5K-98.7%
Quanterix Corporation logo
Quanterix CorporationQTRX
$340K-49.1%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$400K+300%
Revvity logo
RevvityRVTY
$5.44M+107%
Agilent Technologies logo
Agilent TechnologiesA
$1M0.0%

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$9.3B+30.0%
Enterprise value$9.78B+19.3%
P/E55.1×+32.7×
P/S3.6×+0.8×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:19 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000012208-26-000035
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Net cash provided by (used in) investing activities(93.2)2.9
Cash flows from financing activities:
Payments on long-term debt(0.1)(0.1)
Proceeds from issuance of common stock and from reissuance of treasury stock under the employee stock purchase plan and upon exercise of stock options3.44.3
Payments for purchases of treasury stock(47.8)(101.9)
Option premium proceeds for structured purchases of treasury stock0.5
Net cash used in financing activities(44.0)(97.7)
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash5.9(1.8)

Item 1. Financial Statements (Unaudited)

FAQ

What is Bio-Rad Laboratories's stock issuance proceeds?
Bio-Rad Laboratories (BIO) reported stock issuance proceeds of $3.4M in Q1 2026.
How has Bio-Rad Laboratories's stock issuance proceeds changed year-over-year?
Bio-Rad Laboratories's stock issuance proceeds decreased by 20.9% year-over-year, from $4.3M to $3.4M.
What is the long-term trend for Bio-Rad Laboratories's stock issuance proceeds?
Over 4 years (2021 to 2025), Bio-Rad Laboratories's stock issuance proceeds has grown at a -8.3% compound annual growth rate (CAGR), from -$22.32M to $15.8M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Ask your AI about Bio-Rad Laboratories's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude